b3 bio inc. today announced that it has signed an agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to source and develop innovative early stage technologies that could result in potential therapeutic benefits for patients. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as providing development funds.
Dani Bolognesi, CEO and Chairman of b3 bio said, "We are delighted to continue our existing relationship with Roche through this initiative. We believe we are ideally positioned to work with academia to identify promising emerging technologies with unique therapeutic potential and to move these forward in development in conjunction with Roche."
About b3 bio:
b3 bio inc. is an early stage biotechnology company in Research Triangle Park, North Carolina with an initial focus of developing delivery systems for a variety of therapeutic and diagnostic cargos applicable to a broad range of human diseases. b3 bio executed an ongoing collaboration with Roche in this area of technology in July, 2008. b3 bio is situated at The Hamner Institutes for Health Sciences as part of its Accelerator for Translational Bioscience.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment